BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493-496. [PMID: 3371868 DOI: 10.1002/hep.1840080310] [Cited by in Crossref: 414] [Cited by in F6Publishing: 380] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425-33. [PMID: 19669245 DOI: 10.1007/s12072-009-9140-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 6.6] [Reference Citation Analysis]
2 Su MH, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P, Liu ZH, Xie R, He LX, Fu WD, Jiang JN. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol. 2015;21:13087-13094. [PMID: 26673249 DOI: 10.3748/wjg.v21.i46.13087] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000;33:301-7. [PMID: 10952248 DOI: 10.1016/s0168-8278(00)80371-2] [Cited by in Crossref: 137] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
4 Lisker-melman M, Sayuk GS. Defining Optimal Therapeutic Outcomes in Chronic Hepatitis. Archives of Medical Research 2007;38:652-60. [DOI: 10.1016/j.arcmed.2006.10.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
5 Dai C, Chuang W, Jen Hou N, Lee L, Hsieh M, Lin Z, Chen S, Huang J, Hsieh M, Wang L, Tsai J, Wen-yu, Yu M. Early mortality in taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors. Clinical Therapeutics 2006;28:2081-92. [DOI: 10.1016/j.clinthera.2006.12.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
6 Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971-975. [PMID: 10051505 DOI: 10.1002/hep.510290312] [Cited by in Crossref: 315] [Cited by in F6Publishing: 278] [Article Influence: 14.3] [Reference Citation Analysis]
7 Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG. Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B: . PharmacoEconomics 2007;25:963-77. [DOI: 10.2165/00019053-200725110-00006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
8 Wu J, Wu Q, Wu M, Mao W. Serum Cystatin C Predicts Mortality in HBV-Related Decompensated Cirrhosis. Biomed Res Int 2019;2019:7272045. [PMID: 30949507 DOI: 10.1155/2019/7272045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Dakin H, Sherman M, Fung S, Fidler C, Bentley A. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. Pharmacoeconomics 2011;29:1075-91. [PMID: 22077579 DOI: 10.2165/11589260-000000000-00000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
10 He X, Liu X, Peng S, Han Z, Shen J, Cai M. Association of Low High-Density Lipoprotein Cholesterol Levels with Poor Outcomes in Hepatitis B-Associated Decompensated Cirrhosis Patients. Biomed Res Int 2021;2021:9927330. [PMID: 34355041 DOI: 10.1155/2021/9927330] [Reference Citation Analysis]
11 Zhou J, Mao W, Shen L, Huang H. Plasma D-dimer as a novel biomarker for predicting poor outcomes in HBV-related decompensated cirrhosis. Medicine (Baltimore) 2019;98:e18527. [PMID: 31876748 DOI: 10.1097/MD.0000000000018527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
12 Sung JJY, Tsoi KKF, Wong VWS, Li KCT, Chan HLY. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2008;28:1067-77. [DOI: 10.1111/j.1365-2036.2008.03816.x] [Cited by in Crossref: 260] [Cited by in F6Publishing: 236] [Article Influence: 20.0] [Reference Citation Analysis]
13 Bahrami H, Daryani NE, Haghpanah B, Moayyeri A, Moghadam KF, Mirmomen S, Kamangar F. Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial. Am J Gastroenterol 2005;100:856-61. [PMID: 15784032 DOI: 10.1111/j.1572-0241.2005.41144.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
14 Imperial J. Natural history of chronic hepatitis B and C. Journal of Gastroenterology and Hepatology 2009;14:S1-5. [DOI: 10.1046/j.1440-1746.1999.01903.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
15 Chang ML, Tsou YK, Hu TH, Lin CH, Lin WR, Sung CM, Chen TH, Cheng ML, Chang KC, Chiu CT, Yeh CT, Pang JH, Shiao MS. Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance. PLoS One. 2014;9:e104783. [PMID: 25122116 DOI: 10.1371/journal.pone.0104783] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
16 Yip VS, Cheung TT, Poon RT, Yau T, Fung J, Dai WC, Chan AC, Chok SH, Chan SC, Lo CM. Does hepatitis B seroconversion affect survival outcome in patients with hepatitis B related hepatocellular carcinoma? Transl Gastroenterol Hepatol. 2016;1:51. [PMID: 28138618 DOI: 10.21037/tgh.2016.05.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Yeh CT, Shen CH, Tai DI, Chu CM, Liaw YF. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene. 2000;19:5213-5220. [PMID: 11077437 DOI: 10.1038/sj.onc.1203903] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 2.3] [Reference Citation Analysis]
18 Gordon A, McLean CA, Pedersen JS, Bailey MJ, Roberts SK. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol. 2005;43:38-44. [PMID: 15876468 DOI: 10.1016/j.jhep.2005.01.031] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 6.1] [Reference Citation Analysis]
19 Niederau C. Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014;20:11595-617. [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
20 Walter SR, Thein H, Amin J, Gidding HF, Ward K, Law MG, George J, Dore GJ. Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006. Journal of Hepatology 2011;54:879-86. [DOI: 10.1016/j.jhep.2010.08.035] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
21 You S, Yang H, Chen C. Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. Annals of Medicine 2009;36:215-24. [DOI: 10.1080/07853890310021580] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
22 Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, Liaw YF. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology. 2009;49:1859-1867. [PMID: 19378345 DOI: 10.1002/hep.22878] [Cited by in Crossref: 111] [Cited by in F6Publishing: 97] [Article Influence: 9.3] [Reference Citation Analysis]
23 Tsai WL, Lo GH, Hsu PI, Lai KH, Lin CK, Chan HH, Chen WC, Cheng JS, Liu YC, Huang TS, Ger LP, Lin HH. Role of genotype and precore/basal core promoter mutations of hepatitis B virus in patients with chronic hepatitis B with acute exacerbation. Scand J Gastroenterol. 2008;43:196-201. [PMID: 18224565 DOI: 10.1080/00365520701745693] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
24 Wong GL, Yiu KK, Wong VW, Tsoi KK, Chan HL. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:1059-1068. [PMID: 20807216 DOI: 10.1111/j.1365-2036.2010.04447.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
25 Jeng WJ, Liaw YF. Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis. Semin Liver Dis 2021;41:349-57. [PMID: 34182587 DOI: 10.1055/s-0041-1729973] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 . Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia–Pacific region 1: CORE WORKING PARTY FOR ASIA–PACIFIC CONSENSUS ONHEPATITIS B AND C 2. Journal of Gastroenterology and Hepatology 2001;15:825-39. [DOI: 10.1046/j.1440-1746.2000.02324.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 2.9] [Reference Citation Analysis]
27 Pungpapong S, Kim WR. In the eye of the B-holder: Natural history of chronic hepatitis B. Hepatology 2013;58:6-8. [DOI: 10.1002/hep.26356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat. 2005;12:386-392. [PMID: 15985009 DOI: 10.1111/j.1365-2893.2005.00608.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
29 Chu CM, Lin CC, Chen YC, Jeng WJ, Lin SM, Liaw YF. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. Br J Cancer 2012;107:2010-5. [PMID: 23079574 DOI: 10.1038/bjc.2012.474] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
30 Kaplan DE, Reddy KR. Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. Clin Liver Dis 2003;7:683-714. [PMID: 14509534 DOI: 10.1016/s1089-3261(03)00060-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
31 Ferreira MS. Diagnóstico e tratamento da hepatite B. Rev Soc Bras Med Trop 2000;33:389-400. [DOI: 10.1590/s0037-86822000000400010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Chen YP, Zhang Q, Dai L, Liang XE, Peng J, Hou JL. Is transient elastography valuable for high-risk esophageal varices prediction in patients with hepatitis-B-related cirrhosis? J Gastroenterol Hepatol. 2012;27:533-539. [PMID: 21871027 DOI: 10.1111/j.1440-1746.2011.06889.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
33 Chook JB, Ngeow YF, Yap SF, Tan TC, Mohamed R. Combined use of wild-type HBV precore and high serum iron marker as a potential tool for the prediction of cirrhosis in chronic Hepatitis B infection. J Med Virol 2011;83:594-601. [DOI: 10.1002/jmv.22016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
34 Huang MA, Lok AS. Natural history of hepatitis B and outcomes after liver transplantation. Clin Liver Dis 2003;7:521-36. [PMID: 14509524 DOI: 10.1016/s1089-3261(03)00054-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Hunt CM, Brown NA, Rubin M. Lamivudine therapy of chronic hepatitis B. Adv Exp Med Biol 1999;458:11-21. [PMID: 10549375 DOI: 10.1007/978-1-4615-4743-3_2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
36 Hollinger FB, Lau DT. Hepatitis B: The Pathway to Recovery Through Treatment. Gastroenterology Clinics of North America 2006;35:425-61. [DOI: 10.1016/j.gtc.2006.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
37 Lok ASF, Ma OCK. Hepatitis B virus replication in chinese patients with hepatocellular carcinoma. Hepatology 1990;12:582-8. [DOI: 10.1002/hep.1840120322] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
38 Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522-1527. [PMID: 12029639 DOI: 10.1053/jhep.2002.33638] [Cited by in Crossref: 456] [Cited by in F6Publishing: 402] [Article Influence: 24.0] [Reference Citation Analysis]
39 Mels GC, Bellati G, Leandro G, Brunetto MR, Vicari O, Borzio M, Piantino P, Fornaciari G, Scudeller G, Angeli G. Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations. Liver. 1994;14:175-181. [PMID: 7968277 DOI: 10.1111/j.1600-0676.1994.tb00071.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 1.5] [Reference Citation Analysis]
40 Sánchez-tapias JM. Fármacos para el tratamiento de la hepatitis B crónica. Gastroenterología y Hepatología 2008;31:120-8. [DOI: 10.1157/13116500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3.] [Reference Citation Analysis]
42 Jeng WJ, Chien RN, Liaw YF. Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy. Lancet Infect Dis 2021;21:910-1. [PMID: 34174230 DOI: 10.1016/S1473-3099(21)00317-0] [Reference Citation Analysis]
43 Paradis V, Mathurin P, Laurent A, Charlotte F, Vidaud M, Poynard T, Hoang C, Opolon P, Bedossa P. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol. 1996;49:998-1004. [PMID: 9038738 DOI: 10.1136/jcp.49.12.998] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.3] [Reference Citation Analysis]
44 Liu XD, Wu JL, Liang J, Zhang T, Sheng QS. Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients. World J Gastroenterol. 2012;18:2784-2792. [PMID: 22719186 DOI: 10.3748/wjg.v18.i22.2784] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
45 Tong MJ, Hsu L, Chang PW, Blatt LM. Evaluation of current treatment recommendations for chronic hepatitis B: A 2011 update: Treatment guidelines for hepatitis B. Journal of Gastroenterology and Hepatology 2011;26:829-35. [DOI: 10.1111/j.1440-1746.2011.06623.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
46 Liu W, Hu T, Wang X, Chen Y, Huang M, Yuan C, Guan M. Coexistence of hepatitis B surface antigen and anti-HBs in Chinese chronic hepatitis B virus patients relating to genotype C and mutations in the S and P gene reverse transcriptase region. Arch Virol 2012;157:627-34. [PMID: 22222283 DOI: 10.1007/s00705-011-1215-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
47 Hui CK, Lau GK. Treatment of Hepatitis B e Antigen-negative Patients. Curr Treat Options Gastroenterol 2007;10:474-82. [PMID: 18221608 DOI: 10.1007/s11938-007-0047-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
48 Gotsman I, Beinart R, Alper R, Rabbani E, Engelhardt D, Ilan Y. Induction of oral tolerance towards hepatitis B envelope antigens in a murine model. Antiviral Res. 2000;48:17-26. [PMID: 11080537 DOI: 10.1016/s0166-3542(00)00113-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
49 Tian F, Houle SKD, Alsabbagh MW, Wong WWL. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada. Pharmacoeconomics 2020;38:181-92. [PMID: 31691902 DOI: 10.1007/s40273-019-00852-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
50 Wu CS, Lee TY, Chou RH, Yen CJ, Huang WC, Wu CY, Yu YL. Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus-related hepatocellular carcinoma. PLoS One. 2014;9:e99959. [PMID: 24927126 DOI: 10.1371/journal.pone.0099959] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
51 Cai M, Han Z, He X, Zhang J. Usefulness of International Normalized Ratio to Albumin Ratio for Evaluation of Mortality in Hepatitis B Virus-Associated Decompensated Cirrhosis. Biomed Res Int 2021;2021:6664574. [PMID: 34055994 DOI: 10.1155/2021/6664574] [Reference Citation Analysis]
52 Veenstra DL, Sullivan SD, Dusheiko GM, Jacobs M, Aledort JE, Lewis G, Patel KK. Cost-effectiveness of peginterferon α-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom: . European Journal of Gastroenterology & Hepatology 2007;19:631-8. [DOI: 10.1097/meg.0b013e3281108079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
53 Chu C, Liaw Y. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007;14:147-52. [DOI: 10.1111/j.1365-2893.2006.00810.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 7.9] [Reference Citation Analysis]
54 Fontana RJ, Hann HL, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719-27. [DOI: 10.1053/gast.2002.35352] [Cited by in Crossref: 186] [Cited by in F6Publishing: 151] [Article Influence: 9.8] [Reference Citation Analysis]
55 Bárcena Marugán R, García Garzón S. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol 2009;15:423-30. [PMID: 19152446 DOI: 10.3748/wjg.15.423] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
56 Scotto G, Fazio V, Campanozzi F, D'adduzio A. Efficacy of treatment with lamivudine in patients with chronic active E-minus variant hepatitis B virus infection: A nonrandomized, open-label study. Current Therapeutic Research 2000;61:321-30. [DOI: 10.1016/s0011-393x(00)80001-6] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
57 Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, Ierardi E, Amoruso A, Panella C, Francavilla A. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol. 2001;35:805-810. [PMID: 11738109 DOI: 10.1016/s0168-8278(01)00201-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 4] [Article Influence: 2.1] [Reference Citation Analysis]
58 Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 1993;21:303-8. [PMID: 8514896 DOI: 10.1002/jcu.1870210502] [Cited by in Crossref: 134] [Cited by in F6Publishing: 124] [Article Influence: 4.8] [Reference Citation Analysis]
59 Liaw Y. Results of lamivudine trials in Asia. Journal of Hepatology 2003;39:111-5. [DOI: 10.1016/s0168-8278(03)00155-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
60 Arase Y, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Sato J. Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance. Intervirology. 2007;50:161-165. [PMID: 17259734 DOI: 10.1159/000098958] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
61 Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int 2007;1:311-5. [PMID: 19669355 DOI: 10.1007/s12072-007-9002-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
62 Halegoua-De Marzio D, Hann HW. Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol. 2014;20:401-413. [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
63 Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29 Suppl 1:100-107. [PMID: 19207972 DOI: 10.1111/j.1478-3231.2008.01941.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 129] [Article Influence: 12.1] [Reference Citation Analysis]
64 Liaw Y, Leung N, Guan R, Lau GK, Merican I, Mccaughan G, Gane E, Kao J, Omata M; for the Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-89. [DOI: 10.1111/j.1478-3231.2005.01134.x] [Cited by in Crossref: 239] [Cited by in F6Publishing: 226] [Article Influence: 14.9] [Reference Citation Analysis]
65 Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257-265. [PMID: 12586290 DOI: 10.1016/s0168-8278(02)00413-0] [Cited by in Crossref: 286] [Cited by in F6Publishing: 91] [Article Influence: 15.9] [Reference Citation Analysis]
66 Muroyama R, Kato N, Yoshida H, Otsuka M, Moriyama M, Wang Y, Shao RX, Dharel N, Tanaka Y, Ohta M. Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. J Hepatol. 2006;45:805-812. [PMID: 17050029 DOI: 10.1016/j.jhep.2006.07.025] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 3.7] [Reference Citation Analysis]
67 Liaw YF. Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros. Dig Liver Dis 2010;42 Suppl 3:S293-7. [PMID: 20547317 DOI: 10.1016/S1590-8658(10)60519-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
68 Fujiwara A, Sakaguchi K, Fujioka S, Iwasaki Y, Senoh T, Nishimura M, Terao M, Shiratori Y. Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels. J Gastroenterol 2008;43:484-91. [PMID: 18600393 DOI: 10.1007/s00535-008-2183-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
69 Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection - EASL Special Conference. J Hepatol. 2015;63:1238-1253. [PMID: 26150256 DOI: 10.1016/j.jhep.2015.06.026] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 12.2] [Reference Citation Analysis]
70 ter Borg F, ten Kate FJ, Cuypers HT, Leentvaar-Kuijpers A, Oosting J, Wertheim-van Dillen PM, Honkoop P, Rasch MC, de Man RA, van Hattum J, Chamuleau RA, Tytgat GN, Jones EA. A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals. J Clin Pathol 2000;53:541-8. [PMID: 10961179 DOI: 10.1136/jcp.53.7.541] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
71 Liu CC, Wang YH, Chuang EY, Tsai MH, Chuang YH, Lin CL, Liu CJ, Hsiao BY, Lin SM, Liu LY. Identification of a liver cirrhosis signature in plasma for predicting hepatocellular carcinoma risk in a population-based cohort of hepatitis B carriers. Mol Carcinog. 2014;53:58-66. [PMID: 22911910 DOI: 10.1002/mc.21952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
72 Paradis V, Mathurin P, Kollinger M, Imbert-Bismut F, Charlotte F, Piton A, Opolon P, Holstege A, Poynard T, Bedossa P. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997;50:401-6. [PMID: 9215123 DOI: 10.1136/jcp.50.5.401] [Cited by in Crossref: 147] [Cited by in F6Publishing: 132] [Article Influence: 6.1] [Reference Citation Analysis]
73 Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal. Hepatology 1995;22:1863-73. [DOI: 10.1002/hep.1840220636] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
74 van Nunen A, Janssen H, Wolters L, Niesters H, de Man R, Schalm S. Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug? Antiviral Research 2001;52:139-46. [DOI: 10.1016/s0166-3542(01)00178-4] [Cited by in Crossref: 14] [Article Influence: 0.7] [Reference Citation Analysis]
75 Perrillo RP. Interferon in the management of chronic hepatitis B. Digest Dis Sci 1993;38:577-93. [DOI: 10.1007/bf01316785] [Cited by in Crossref: 63] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
76 Campbell MS, Reddy KR. Review article: the evolving role of liver biopsy. Aliment Pharmacol Ther. 2004;20:249-259. [PMID: 15274661 DOI: 10.1111/j.1365-2036.2004.02071.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
77 Villa E, Fattovich G, Mauro A, Pasino M. Natural history of chronic HBV infection: special emphasis on the prognostic implications of the inactive carrier state versus chronic hepatitis. Digestive and Liver Disease 2011;43:S8-S14. [DOI: 10.1016/s1590-8658(10)60686-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
78 Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084-1089. [PMID: 12360470 DOI: 10.1053/gast.2002.36026] [Cited by in Crossref: 233] [Cited by in F6Publishing: 201] [Article Influence: 12.3] [Reference Citation Analysis]
79 O’Sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust N Z J Public Health. 2004;28:212-216. [PMID: 15707165 DOI: 10.1111/j.1467-842x.2004.tb00697.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
80 Nash KL, Alexander GJ, Lever AM. Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes. J Viral Hepat. 2005;12:346-356. [PMID: 15985004 DOI: 10.1111/j.1365-2893.2005.00612.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
81 Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc. 2007;82:967-975. [PMID: 17673066 DOI: 10.4065/82.8.967] [Cited by in Crossref: 134] [Cited by in F6Publishing: 106] [Article Influence: 9.6] [Reference Citation Analysis]
82 Lin SM, Tai DI, Chien RN, Sheen IS, Chu CM, Liaw YF. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat. 2004;11:349-357. [PMID: 15230858 DOI: 10.1111/j.1365-2893.2004.00512.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
83 Shi M, Zhang Y, Zhu YH, Zhang J, Xu WJ. Comparison of real-time polymerase chain reaction with the COBAS Amplicor test for quantitation of hepatitis B virus DNA in serum samples. World J Gastroenterol 2008;14:479-83. [PMID: 18200674 DOI: 10.3748/wjg.14.479] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
84 Sali S, Alavian SM, Foster GR, Keyvani H, Mehrnoosh L, Mohammadi N. Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up. Hepat Mon 2013;13:e8743. [PMID: 24066002 DOI: 10.5812/hepatmon.8743] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
85 Lin H, Shyu W, Chen G, Lin Y, Chen T, Liaw Y. DNA measurements in chronic hepatitis, cirrhosis and hepatocellular carcinoma. Liver 1990;10:313-8. [DOI: 10.1111/j.1600-0676.1990.tb00474.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
86 Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B. J Med Virol 2007;79:1286-92. [DOI: 10.1002/jmv.20928] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
87 Chang ML, Jeng WJ, Liaw YF. Clinical events after cessation of lamivudine therapy in patients recovered from hepatitis B flare with hepatic decompensation. Clin Gastroenterol Hepatol 2015;13:979-86. [PMID: 25445774 DOI: 10.1016/j.cgh.2014.10.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
88 Zampino R, Marrone A, Cirillo G, del Giudice EM, Utili R, Karayiannis P, Liang TJ, Ruggiero G. Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment. J Viral Hepat. 2002;9:183-188. [PMID: 12010505 DOI: 10.1046/j.1365-2893.2002.00347.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
89 Sarin SK, Sandhu BS, Sharma BC, Jain M, Singh J, Malhotra V. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*. J Viral Hepat 2004;11:552-8. [DOI: 10.1111/j.1365-2893.2004.00542.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
90 Strasser SI, Mccaughan GW. Therapies for chronic hepatitis B: emerging roles for nucleoside analogues. Australian and New Zealand Journal of Medicine 2000;30:556-8. [DOI: 10.1111/j.1445-5994.2000.tb00855.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
91 Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999;29:889-896. [PMID: 10051494 DOI: 10.1002/hep.510290321] [Cited by in Crossref: 346] [Cited by in F6Publishing: 303] [Article Influence: 15.7] [Reference Citation Analysis]
92 Burns GS, Thompson AJ. Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med. 2014;4:a024935. [PMID: 25359547 DOI: 10.1101/cshperspect.a024935] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
93 Chu CM, Shyu WC, Liaw YF. Comparative studies on expression of alpha-smooth muscle actin in hepatic stellate cells in chronic hepatitis B and C. Dig Dis Sci. 2008;53:1364-1369. [PMID: 17934809 DOI: 10.1007/s10620-007-9997-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
94 Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What's the future holding for us? World J Gastroenterol. 2015;21:12558-12575. [PMID: 26640332 DOI: 10.3748/wjg.v21.i44.12558] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
95 Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003;39:222-230. [PMID: 12873819 DOI: 10.1016/s0168-8278(03)00171-5] [Cited by in Crossref: 233] [Cited by in F6Publishing: 79] [Article Influence: 13.7] [Reference Citation Analysis]
96 You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, Tang BZ, Huang ML, Ma YL, Chongsuvivatwong V, Sriplung H, Geater A, Qiao YW, Wu RX. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol 2006;12:6715-21. [PMID: 17075991 DOI: 10.3748/wjg.v12.i41.6715] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
97 Sheen IS, Liaw YF. The prevalence and incidence of cholecystolithiasis in patients with chronic liver diseases: a prospective study. Hepatology. 1989;9:538-540. [PMID: 2925157 DOI: 10.1002/hep.1840090405] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 1.2] [Reference Citation Analysis]
98 Zhang H, Sun Q, Mao W, Fan J, Ye B. Neutrophil-to-Lymphocyte Ratio Predicts Early Mortality in Patients with HBV-Related Decompensated Cirrhosis. Gastroenterol Res Pract. 2016;2016:4394650. [PMID: 26949385 DOI: 10.1155/2016/4394650] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
99 Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002;36:263-270. [PMID: 11830339 DOI: 10.1016/s0168-8278(01)00266-5] [Cited by in Crossref: 231] [Cited by in F6Publishing: 60] [Article Influence: 12.2] [Reference Citation Analysis]
100 Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744-749. [PMID: 15082595 DOI: 10.1136/gut.2003.020263] [Cited by in Crossref: 315] [Cited by in F6Publishing: 269] [Article Influence: 18.5] [Reference Citation Analysis]
101 Chon YE, Jung ES, Park JY, Kim DY, Ahn SH, Han KH, Chon CY, Jung KS, Kim SU. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol. 2012;46:518-525. [PMID: 22688146 DOI: 10.1097/mcg.0b013e31825079f1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
102 Liaw Y, Lin S, Chen T, Chien R, Sheen I, Chu C. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial. Journal of Hepatology 1994;20:175-80. [DOI: 10.1016/s0168-8278(05)80055-8] [Cited by in Crossref: 54] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
103 Mcmahon BJ. Chronic carriers of hepatitis B virus who clear hepatitis B surface antigen: Are they really ?off the hook?? Hepatology 1998;28:265-7. [DOI: 10.1002/hep.510280135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
104 McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis. 2010;14:381-396. [PMID: 20638020 DOI: 10.1016/j.cld.2010.05.007] [Cited by in Crossref: 113] [Cited by in F6Publishing: 91] [Article Influence: 10.3] [Reference Citation Analysis]
105 Hsiao TJ, Liao HW, Hsieh PS, Wong RH. Risk of betel quid chewing on the development of liver cirrhosis: a community-based case-control study. Ann Epidemiol 2007;17:479-85. [PMID: 17448681 DOI: 10.1016/j.annepidem.2006.12.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
106 Yeh CT, Hsu CW, Chen YC, Liaw YF. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J Clin Virol. 2009;45:114-118. [PMID: 19451024 DOI: 10.1016/j.jcv.2009.04.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
107 Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, Realdi G, Ruol A. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991;32:294-298. [PMID: 2013423 DOI: 10.1136/gut.32.3.294] [Cited by in Crossref: 290] [Cited by in F6Publishing: 261] [Article Influence: 9.7] [Reference Citation Analysis]
108 Yeh C, Sheen I, Chen T, Hsieh S, Chu C, Liaw Y. Prednisolone modulates the therapeutic effect of interferon to eliminate preferentially the hepatitis B virus precore stop mutant. Journal of Hepatology 2000;32:829-36. [DOI: 10.1016/s0168-8278(00)80253-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-11] [Cited by in Crossref: 91] [Cited by in F6Publishing: 52] [Article Influence: 10.1] [Reference Citation Analysis]
110 Chen D. Natural history of chronic hepatitis B virus infection: New light on an old story. J Gastroenterol Hepatol 1993;8:470-5. [DOI: 10.1111/j.1440-1746.1993.tb01551.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 1.8] [Reference Citation Analysis]
111 Di Marco V, Lo Iacono O, Cammà C, Vaccaro A, Giunta M, Martorana G, Fuschi P, Almasio PL, Craxì A. The long-term course of chronic hepatitis B. Hepatology 1999;30:257-64. [PMID: 10385664 DOI: 10.1002/hep.510300109] [Cited by in Crossref: 154] [Cited by in F6Publishing: 139] [Article Influence: 7.0] [Reference Citation Analysis]
112 Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, Ono M, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Imajo K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:1300-1306. [PMID: 21750883 DOI: 10.1007/s00535-011-0436-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 6.6] [Reference Citation Analysis]
113 Craxı̀ A, Di Bona D, Cammà C. Interferon-α for HBeAg-positive chronic hepatitis B. Journal of Hepatology 2003;39:99-105. [DOI: 10.1016/s0168-8278(03)00154-5] [Cited by in Crossref: 56] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
114 Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45-52. [PMID: 17107734 DOI: 10.1016/j.jhep.2006.08.021] [Cited by in Crossref: 223] [Cited by in F6Publishing: 202] [Article Influence: 14.9] [Reference Citation Analysis]
115 Zhang N, Reijnders JGP, Perquin M, Hansen BE, Janssen HLA. Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B. Journal of Viral Hepatitis 2011;18. [DOI: 10.1111/j.1365-2893.2011.01448.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
116 Hige S, Yamamoto Y, Yoshida S, Kobayashi T, Horimoto H, Yamamoto K, Sho T, Natsuizaka M, Nakanishi M, Chuma M, Asaka M. Sensitive assay for quantification of hepatitis B virus mutants by use of a minor groove binder probe and peptide nucleic acids. J Clin Microbiol 2010;48:4487-94. [PMID: 20926703 DOI: 10.1128/JCM.00731-10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
117 Terrault NA, Wright TL. Therapy for Chronic Hepatitis B Infection. In: Mills J, Volberding PA, Corey L, editors. Antiviral Chemotherapy 4. Boston: Springer US; 1996. pp. 189-205. [DOI: 10.1007/978-1-4757-9209-6_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
118 Galan MV, Boyce D, Gordon SC. Current pharmacotherapy for hepatitis B infection. Expert Opin Pharmacother. 2001;2:1289-1298. [PMID: 11584997 DOI: 10.1517/14656566.2.8.1289] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
119 Hui CK, Lie A, Au WY, Leung YH, Ma SY, Cheung WW, Zhang HY, Chim CS, Kwong YL, Liang R, Lau GK. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005;106:464-9. [PMID: 15797991 DOI: 10.1182/blood-2005-02-0698] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
120 Nishida T, Kobashi H, Fujioka S, Fujio K, Takaguchi K, Ikeda H, Kawaguchi M, Ando M, Araki Y, Higashi T. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol. 2008;23:794-803. [PMID: 18086120 DOI: 10.1111/j.1440-1746.2007.05240.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
121 Yuen MF, Lai CL. Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2000;15 Suppl:E20-E24. [PMID: 10921377 DOI: 10.1046/j.1440-1746.2000.02123.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 2.2] [Reference Citation Analysis]
122 Robinson WS. The role of hepatitis B virus in the development of primary hepatocellular carcinoma: Part I. J Gastroenterol Hepatol 1992;7:622-38. [DOI: 10.1111/j.1440-1746.1992.tb01497.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
123 Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2:163-186. [PMID: 28042609 DOI: 10.20517/2394-5079.2016.05] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 12.8] [Reference Citation Analysis]
124 Frenette CT, Gish RG. To "be" or not to "be": that is the question. Am J Gastroenterol 2009;104:1948-52. [PMID: 19661938 DOI: 10.1038/ajg.2009.204] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
125 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms20061358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 29.5] [Reference Citation Analysis]
126 Oh JM, Kyun J, Cho SW. Long-term lamivudine therapy for chronic hepatitis B in patients with and without cirrhosis. Pharmacotherapy. 2002;22:1226-1234. [PMID: 12389873 DOI: 10.1592/phco.22.15.1226.33479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
127 Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res 2021;149:1-61. [PMID: 33579421 DOI: 10.1016/bs.acr.2020.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
128 Buti M, Oyagüez I, Lozano V, Casado MA. Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B: a systematic review. Pharmacoeconomics. 2013;31:63-75. [PMID: 23329593 DOI: 10.1007/s40273-012-0009-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
129 Byrne R, Carey I, Agarwal K. Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Therap Adv Gastroenterol 2018;11:1756284818786108. [PMID: 30034532 DOI: 10.1177/1756284818786108] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
130 Kim DJ, Cho EJ, Yu KS, Jang IJ, Yoon JH, Park T, Cho JY. Comprehensive Metabolomic Search for Biomarkers to Differentiate Early Stage Hepatocellular Carcinoma from Cirrhosis. Cancers (Basel). 2019;11. [PMID: 31590436 DOI: 10.3390/cancers11101497] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
131 Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177-1185. [PMID: 22871500 DOI: 10.1016/j.jhep.2012.07.031] [Cited by in Crossref: 78] [Cited by in F6Publishing: 63] [Article Influence: 8.7] [Reference Citation Analysis]
132 Villeneuve J, Desrochers M, Infante-rivard C, Willems B, Raymond G, Bourcier M, Côté J, Richer G. A long-term follow-up study of asymptomatic hepatitis B surface antigen—Positive carriers in montreal. Gastroenterology 1994;106:1000-5. [DOI: 10.1016/0016-5085(94)90760-9] [Cited by in Crossref: 126] [Cited by in F6Publishing: 110] [Article Influence: 4.7] [Reference Citation Analysis]
133 Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47:760-767. [PMID: 17928090 DOI: 10.1016/j.jhep.2007.07.022] [Cited by in Crossref: 211] [Cited by in F6Publishing: 189] [Article Influence: 15.1] [Reference Citation Analysis]
134 Han SH. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B. Drugs 2006;66:1831-51. [PMID: 17040114 DOI: 10.2165/00003495-200666140-00005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
135 Zhang J, Qiu Y, He X, Mao W, Han Z. Platelet-to-white blood cell ratio: A novel and promising prognostic marker for HBV-associated decompensated cirrhosis. J Clin Lab Anal 2020;34:e23556. [PMID: 32893950 DOI: 10.1002/jcla.23556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Nguyen MH, Garcia G. Does isoniazid cause more serious hepatotoxicity in hepatitis B virus carriers? Am J Gastroenterology 2002;97:1092-3. [DOI: 10.1111/j.1572-0241.2002.05700.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
137 Sigal SH, Ala A, Ivanov K, Hossain S, Bodian C, Schiano TD, Min AD, Bodenheimer HC, Thung SN. Histopathology and clinical correlates of end-stage hepatitis B cirrhosis: A possible mechanism to explain the response to antiviral therapy. Liver Transpl 2005;11:82-8. [DOI: 10.1002/lt.20328] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
138 Liaw Y. Natural History of Chronic Hepatitis B Virus Infection. In: Thomas HC, Lok AS, Locarnini SA, Zuckerman AJ, editors. Viral Hepatitis. Oxford: John Wiley & Sons, Ltd; 2013. pp. 143-53. [DOI: 10.1002/9781118637272.ch10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res. 2007;75:146-151. [PMID: 17400303 DOI: 10.1016/j.antiviral.2007.02.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
140 Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S, Njie R, Njai H, Lemoine M, Hallett TB, Thursz M. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Glob Health 2016;4:e568-78. [PMID: 27443782 DOI: 10.1016/S2214-109X(16)30101-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 22] [Article Influence: 20.3] [Reference Citation Analysis]
141 Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-Effectiveness Analysis of Lamivudine for the Treatment of Chronic Hepatitis B: . PharmacoEconomics 2000;17:409-27. [DOI: 10.2165/00019053-200017050-00001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
142 Poh Z, Goh BB, Chang PE, Tan CK. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients. Eur J Gastroenterol Hepatol. 2015;27:638-643. [PMID: 25831135 DOI: 10.1097/meg.0000000000000341] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 7.4] [Reference Citation Analysis]
143 Tong MJ, Huynh TT, Siripongsakun S, Chang PW, Tong LT, Ha YP, Mena EA, Weissman MF. Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis. Hepatol Int 2015;9:567-77. [PMID: 26219830 DOI: 10.1007/s12072-015-9651-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
144 Yao K, Liu J, Wang J, Yan X, Xia J, Yang Y, Wu W, Liu Y, Chen Y, Zhang Z, Li J, Huang R, Wu C. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat 2021;28:1025-33. [PMID: 33797145 DOI: 10.1111/jvh.13511] [Reference Citation Analysis]
145 Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol. 2008;22:991-1008. [PMID: 19187863 DOI: 10.1016/j.bpg.2008.11.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 5.2] [Reference Citation Analysis]
146 Ahn SH, Chan HL, Chen PJ, Cheng J, Goenka MK, Hou J, Lim SG, Omata M, Piratvisuth T, Xie Q, Yim HJ, Yuen MF; APPROACH Working Group. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int. 2010;4:386-395. [PMID: 20305758 DOI: 10.1007/s12072-010-9163-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
147 Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075. [PMID: 17393513 DOI: 10.1002/hep.21627] [Cited by in Crossref: 407] [Cited by in F6Publishing: 348] [Article Influence: 29.1] [Reference Citation Analysis]
148 Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio K, Fujino H, Nakahara T, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis. Hepatol Res 2018;48:264-74. [PMID: 29114970 DOI: 10.1111/hepr.12996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
149 Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichikawa T, Kodai S, Shinkawa H, Sakaguchi H, Tamori A. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res. 2007;37:94-100. [PMID: 17300703 DOI: 10.1111/j.1872-034x.2007.00013.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
150 Aggarwal R, Ranjan P. Preventing and treating hepatitis B infection. BMJ. 2004;329:1080-1086. [PMID: 15528620 DOI: 10.1136/bmj.329.7474.1080] [Cited by in Crossref: 48] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
151 You J, Zhuang L, Tang BZ, Yang WB, Ding SY, Li W, Wu RX, Zhang HL, Zhang YM, Yan SM. A randomized controlled clinical trial on the treatment of Thymosina1 versus interferon-alpha in patients with hepatitis B. World J Gastroenterol. 2001;7:411-414. [PMID: 11819801 DOI: 10.3748/wjg.v7.i3.411] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
152 Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 1991;13:627-631. [PMID: 2010157 DOI: 10.1002/hep.1840130403] [Cited by in Crossref: 179] [Cited by in F6Publishing: 113] [Article Influence: 6.0] [Reference Citation Analysis]
153 Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, Hadziyannis SJ. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut. 2003;52:404-409. [PMID: 12584224 DOI: 10.1136/gut.52.3.404] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 4.2] [Reference Citation Analysis]
154 Yuen M. Revisiting the natural history of chronic hepatitis B: Impact of new concepts on clinical management. J Gastroenterol Hepatol 2007;22:973-6. [DOI: 10.1111/j.1440-1746.2007.04938.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
155 Gish RG, Yuen MF, Chan HL, Given BD, Lai CL, Locarnini SA, Lau JY, Wooddell CI, Schluep T, Lewis DL. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Res. 2015;121:97-108. [PMID: 26129970 DOI: 10.1016/j.antiviral.2015.06.019] [Cited by in Crossref: 96] [Cited by in F6Publishing: 83] [Article Influence: 16.0] [Reference Citation Analysis]
156 Kim J, Lee SH, Kim HS, Choi K, Jeong SW, Kim SG, Jang JY, Kim YS, Kim BS. Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B. Gut Liver 2015;9:103-8. [PMID: 25287170 DOI: 10.5009/gnl14018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
157 Fattovich G. Natural history of hepatitis B. J Hepatol. 2003;39 Suppl 1:S50-S58. [PMID: 14708678 DOI: 10.1016/s0168-8278(03)00139-9] [Cited by in Crossref: 132] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
158 Sullivan SD, Veenstra DL, Chen PJ, Chang TT, Chuang WL, Tsai C, Patel K. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol 2007;22:1494-9. [PMID: 17716353 DOI: 10.1111/j.1440-1746.2006.04539.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
159 Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119:172-180. [PMID: 10889166 DOI: 10.1053/gast.2000.8559] [Cited by in Crossref: 501] [Cited by in F6Publishing: 432] [Article Influence: 23.9] [Reference Citation Analysis]
160 Chen CH, Lee CM, Wang JH, Tung HD, Hung CH, Lu SN. Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur J Gastroenterol Hepatol. 2004;16:1213-1218. [PMID: 15489584 DOI: 10.1097/00042737-200411000-00021] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
161 Ilan Y, Chowdhury JR. Induction of tolerance to hepatitis B virus: can we 'eat the disease' and live with the virus? Med Hypotheses. 1999;52:505-509. [PMID: 10459829 DOI: 10.1054/mehy.1997.0687] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
162 Wong WW, Hicks LK, Tu HA, Pritchard KI, Krahn MD, Feld JJ, Chan KK. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Res Treat 2015;151:639-52. [PMID: 25962692 DOI: 10.1007/s10549-015-3382-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
163 Huang JF, Yu ML, Lee CM, Dai CY, Hou NJ, Hsieh MY, Wang JH, Lu SN, Sheen IS, Lin SM. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. Aliment Pharmacol Ther. 2007;25:1029-1037. [PMID: 17439503 DOI: 10.1111/j.1365-2036.2007.03297.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
164 Yeh CT, Chang MH, Lai HY, Chang ML, Chu CM, Liaw YF. Identification of a novel pre-S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen. J Gastroenterol Hepatol. 2003;18:1129-1138. [PMID: 12974898 DOI: 10.1046/j.1440-1746.2003.03146.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
165 Hwang SJ, Lu RH, Wood ML, Wang YJ, Chang FY, Lee SD. Comparison of the nucleic acid-based crosslinking hybridization assay and the branched DNA signal amplification assay in the quantitative measurement of serum hepatitis B virus DNA. J Clin Lab Anal. 1999;13:296-300. [PMID: 10633298 DOI: 10.1002/(sici)1098-2825(1999)13:6<296::aid-jcla8>3.0.co;2-c] [Reference Citation Analysis]
166 Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol. 2002;40:1207-1209. [PMID: 11923332 DOI: 10.1128/jcm.40.4.1207-1209.2002] [Cited by in Crossref: 143] [Cited by in F6Publishing: 51] [Article Influence: 7.5] [Reference Citation Analysis]
167 Ismail AM, Sharma OP, Kumar MS, Eapen CE, Kannangai R, Abraham P. Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: An Indian subcontinent perspective. Antiviral Research 2013;98:209-16. [DOI: 10.1016/j.antiviral.2013.02.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
168 O'sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ. Estimates of chronic hepatitis B virus infection in Australia, 2000. Australian and New Zealand Journal of Public Health 2004;28:212-6. [DOI: 10.1111/j.1467-842x.2004.tb00477.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
169 Huang J, Cai M, He X. Serum potassium levels and prognosis in HBV-associated decompensated cirrhosis. J Clin Lab Anal 2021;35:e23775. [PMID: 33951234 DOI: 10.1002/jcla.23775] [Reference Citation Analysis]
170 Rizzetto M, Zanetti AR. Progress in the prevention and control of viral hepatitis type B: closing remarks. J Med Virol. 2002;67:463-466. [PMID: 12116047 DOI: 10.1002/jmv.10098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
171 Fan W, Huang L, Zhou Z, Li Y. A336C/A336T/T337C variations in HBV core gene and spontaneous hepatitis B e antigen loss in chronic hepatitis B patients. Virol J 2011;8:226. [PMID: 21569538 DOI: 10.1186/1743-422X-8-226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
172 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms] [Cited by in Crossref: 22] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
173 Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. Journal of Hepatology 2008;48:335-52. [DOI: 10.1016/j.jhep.2007.11.011] [Cited by in Crossref: 791] [Cited by in F6Publishing: 710] [Article Influence: 60.8] [Reference Citation Analysis]
174 Hung H, Chen TH. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: An experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence. Vaccine 2009;27:6770-6. [DOI: 10.1016/j.vaccine.2009.08.082] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
175 Zacharakis G, Koskinas J, Kotsiou S, Papoutselis M, Tzara F, Vafeiadis N, Archimandritis A, Papoutselis K. Natural history of chronic HBV infection: A cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol 2005;77:173-9. [DOI: 10.1002/jmv.20434] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 4.1] [Reference Citation Analysis]
176 Wong P, Fung T, Mak S, Lo K, Tong GM, Wong Y, Loo C, Lam EK, Wong AK. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol 2005;20:1641-51. [DOI: 10.1111/j.1440-1746.2005.03837.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
177 Hung H, Chen H. Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection: . PharmacoEconomics 2011;29:1063-73. [DOI: 10.2165/11586470-000000000-00000] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
178 Lacey L, Chien R, Chuang W, Pwu R. Economic evaluation of chronic hepatitis B treatments in Taiwan. J Gastroenterol Hepatol 2008;23:571-9. [DOI: 10.1111/j.1440-1746.2008.05360.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
179 Gjørup IE, Skinhøj P. New aspects on the natural history of chronic hepatitis B infection: implication for therapy. Scand J Infect Dis 2003;35:808-13. [PMID: 14723354 DOI: 10.1080/00365540310017168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
180 Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829-834. [PMID: 15178498 DOI: 10.1016/j.amjmed.2003.12.040] [Cited by in Crossref: 199] [Cited by in F6Publishing: 171] [Article Influence: 11.7] [Reference Citation Analysis]
181 Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology. 2010;51:435-444. [PMID: 19918971 DOI: 10.1002/hep.23348] [Cited by in Crossref: 119] [Cited by in F6Publishing: 102] [Article Influence: 10.8] [Reference Citation Analysis]
182 Ruiz-sancho A, Sheldon J, Soriano V. Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opinion on Biological Therapy 2007;7:751-61. [DOI: 10.1517/14712598.7.5.751] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
183 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 943] [Article Influence: 179.3] [Reference Citation Analysis]
184 Ilan Y. Immune downregulation leads to upregulation of an antiviral response: a lesson from the hepatitis B virus. Microbes Infect. 2002;4:1317-1326. [PMID: 12443896 DOI: 10.1016/s1286-4579(02)00012-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
185 Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology. 2008;48:1070-1078. [PMID: 18688879 DOI: 10.1002/hep.22476] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 5.1] [Reference Citation Analysis]
186 Park YH, Kim BK, Kim JK, Kim HC, Kim DY, Park JY, Han K, Kim SU, Shin SH, Hahn KY, Ahn SH. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea: The outcomes of chronic hepatitis B. J Gastroenterol Hepatol 2014;29:1005-11. [DOI: 10.1111/jgh.12478] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
187 Lim L, Tran BM, Vincan E, Locarnini S, Warner N. HBV-related hepatocellular carcinoma: the role of integration, viral proteins and miRNA. Future Virology 2012;7:1237-49. [DOI: 10.2217/fvl.12.113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
188 Chu C. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15:E25-30. [DOI: 10.1046/j.1440-1746.2000.02097.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 104] [Article Influence: 5.5] [Reference Citation Analysis]
189 Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol. 1990;10:29-34. [PMID: 2307827 DOI: 10.1016/0168-8278(90)90069-4] [Cited by in Crossref: 164] [Cited by in F6Publishing: 147] [Article Influence: 5.3] [Reference Citation Analysis]
190 Shermock KM, Temple ME, Younossi ZM. A pharmacoeconomic appraisal of therapies for hepatitis B and C. Expert Opinion on Pharmacotherapy 2005;2:205-11. [DOI: 10.1517/14656566.2.2.205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
191 Li Y, Wang X, Chen F, Ma R, Wen X, Hu L. Clinical significance of a set of single nucleotide polymorphisms of hepatitis B virus core gene in Chinese Han patients with chronic hepatitis B. J Med Virol 2008;80:1885-90. [DOI: 10.1002/jmv.21301] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
192 Maxwell PR, Flisiak R. Changes in serological biomarkers of liver function and connective tissue turnover in chronic hepatitis B during lamivudine therapy. Biomarkers. 2005;10:475-484. [PMID: 16308271 DOI: 10.1080/13547500500353760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
193 Dakin H, Bentley A, Dusheiko G. Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B. Value in Health 2010;13:922-33. [DOI: 10.1111/j.1524-4733.2010.00782.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
194 Liaw YF, Tsai SL, Sheen IS, Chao M, Yeh CT, Hsieh SY, Chu CM. Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol. 1998;93:354-359. [PMID: 9517639 DOI: 10.1111/j.1572-0241.1998.00354.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
195 Chan HL, Hui Y, Leung NW, Ching JY, Chan FK, Sung JJ. Risk Factors for Active Liver Disease in Hbeag-Negative Chronic Hepatitis B Virus–Infected Patients. American Journal of Gastroenterology 2000;95:3547-51. [DOI: 10.1111/j.1572-0241.2000.03373.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
196 Chan HL, Tsang SW, Wong ML, Tse CH, Leung NW, Chan FK, Sung JJ. Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. Am J Gastroenterol. 2002;97:2629-2633. [PMID: 12385451 DOI: 10.1111/j.1572-0241.2002.06065.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
197 Venkatesh SK, Xu S, Tai D, Yu H, Wee A. Correlation of MR elastography with morphometric quantification of liver fibrosis (Fibro-C-Index) in chronic hepatitis B. Magn Reson Med. 2014;72:1123-1129. [PMID: 24166665 DOI: 10.1002/mrm.25002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
198 Merican I. Treatment of chronic hepatitis B virus infection in special groups of patients: decompensated cirrhosis, immunosuppressed and paediatric patients. J Gastroenterol Hepatol 2000;15:E71-8. [DOI: 10.1046/j.1440-1746.2000.02104.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
199 Duarte-rojo A, Feld JJ. Hepatitis B Biomarkers: Clinical Significance of the Old and the New. Curr Hepatitis Rep 2010;9:187-96. [DOI: 10.1007/s11901-010-0053-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
200 Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ;  Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686. [PMID: 16530509 DOI: 10.1053/j.gastro.2005.11.016] [Cited by in Crossref: 1074] [Cited by in F6Publishing: 941] [Article Influence: 71.6] [Reference Citation Analysis]
201 Shih ST, Crowley S, Sheu JC. Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos Med Assoc. 2010;109:39-55. [PMID: 20123585 DOI: 10.1016/s0929-6646(10)60020-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
202 Bortolotti F. Treatment of chronic hepatitis B in children. J Hepatol. 2003;39 Suppl 1:S200-S205. [PMID: 14708704 DOI: 10.1016/s0168-8278(03)00328-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
203 Tsai NC, Holck PS, Wong LL, Ricalde AA. Seroepidemiology of hepatitis B virus infection: analysis of mass screening in Hawaii. Hepatol Int 2008;2:478-85. [PMID: 19669323 DOI: 10.1007/s12072-008-9103-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
204 Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a workshop. Gastroenterology. 2001;120:1828-1853. [PMID: 11375963 DOI: 10.1053/gast.2001.24839] [Cited by in Crossref: 522] [Cited by in F6Publishing: 436] [Article Influence: 26.1] [Reference Citation Analysis]
205 Lok ASF. Does interferon therapy for chronic hepatitis B reduce the risks of developing cirrhosis and hepatocellular carcinoma? Hepatology 1995;22:1336-8. [DOI: 10.1002/hep.1840220447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
206 Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998;27:1383-1387. [PMID: 9581695 DOI: 10.1002/hep.510270527] [Cited by in Crossref: 101] [Cited by in F6Publishing: 95] [Article Influence: 4.4] [Reference Citation Analysis]
207 Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol. 2016;22:8720-8734. [PMID: 27818588 DOI: 10.3748/wjg.v22.i39.8720] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 55] [Article Influence: 17.0] [Reference Citation Analysis]
208 Yamasaki K, Tanaka J, Kurisu A, Akita T, Ohisa M, Sakamune K, Ko K, Sugiyama A, Yasaka T, Shirahama S. Natural course of persistent hepatitis B virus infection in hepatitis B e antigen-positive and hepatitis B e antigen-negative cohorts in Japan based on the Markov model. J Med Virol 2018;90:1800-13. [PMID: 29995323 DOI: 10.1002/jmv.25260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
209 Mattsson L. Chronic non-A, non-B hepatitis with special reference to the transfusion-associated form. Scand J Infect Dis Suppl 1989;59:1-55. [PMID: 2502835 DOI: 10.3109/inf.1988.20.suppl-59.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
210 Xu Y, Zhang YG, Wang X, Qi WQ, Qin SY, Liu ZH, Jiao J, Wang JB. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World J Gastroenterol. 2015;21:7869-7876. [PMID: 26167087 DOI: 10.3748/wjg.v21.i25.7869] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
211 Calvaruso V, Craxì A. Fibrosis in chronic viral hepatitis. Best Pract Res Clin Gastroenterol. 2011;25:219-230. [PMID: 21497740 DOI: 10.1016/j.bpg.2011.02.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
212 Papatheodoridis GV, Hadziyannis SJ. Current management of chronic hepatitis B: REVIEW: CURRENT MANAGEMENT OF CHRONIC HEPATITIS B. Alimentary Pharmacology & Therapeutics 2004;19:25-37. [DOI: 10.1046/j.1365-2036.2003.01810.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
213 Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol 2020;14:565-78. [PMID: 32448008 DOI: 10.1080/17474124.2020.1774364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
214 Zhang YY, Summers J. Rapid production of neutralizing antibody leads to transient hepadnavirus infection. J Virol. 2004;78:1195-1201. [PMID: 14722274 DOI: 10.1128/jvi.78.3.1195-1201.2004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
215 Ma H, Wang J, Guo F, Wei L. α-2-HS-glycoprotein is a potential marker predicting hepatitis B e antigen seroconversion in patients with chronic hepatitis B during treatment with pegylated interferon alpha-2b. Sci China Life Sci. 2011;54:39-47. [PMID: 21253869 DOI: 10.1007/s11427-010-4111-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
216 Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol. 2002;66:435-451. [PMID: 11857520 DOI: 10.1002/jmv.2164] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
217 Chen DK, Yim C, O'rourke K, Krajden M, Wong DK, Heathcote E. Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population. Journal of Hepatology 1999;30:557-63. [DOI: 10.1016/s0168-8278(99)80184-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
218 Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, Jindal S, Hui M, Finlay-Schultz J, Ebrahimie E, Birrell SN, Stelloo S, Iggo R, Alexandrou S, Caldon CE, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med 2021;27:310-20. [PMID: 33462444 DOI: 10.1038/s41591-020-01168-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
219 Zhu S, Waili Y, Qi X, Chen Y, Lou Y, Chen B. Serum C-reactive protein predicts early mortality in hospitalized patients with HBV-related decompensated cirrhosis. Medicine (Baltimore) 2017;96:e5988. [PMID: 28121954 DOI: 10.1097/MD.0000000000005988] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
220 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3] [Cited by in Crossref: 636] [Cited by in F6Publishing: 632] [Article Influence: 48.9] [Reference Citation Analysis]
221 Chen C, Iloeje UH, Yang H. Serum hepatitis B virus DNA as a predictor of the development of cirrhosis and hepatocellular carcinoma. Current Hepatitis Reports 2007;6:9-16. [DOI: 10.1007/bf02942173] [Cited by in Crossref: 12] [Article Influence: 0.9] [Reference Citation Analysis]
222 Alam S, Ahmad N, Mustafa G, Alam K, Khan M. Characteristics of treatment naïve chronic hepatitis B in Bangladesh: younger populations are more affected; HBeAg-negatives are more advanced. Saudi J Gastroenterol 2008;14:15-9. [PMID: 19568488 DOI: 10.4103/1319-3767.37796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
223 Cheng AY, Kong AP, Wong VW, So WY, Chan HL, Ho CS, Lam CW, Tam JS, Chow CC, Cockram CS. Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. Diabetologia. 2006;49:1777-1784. [PMID: 16736132 DOI: 10.1007/s00125-006-0294-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
224 Chen CY, Lu CL, Chang FY, Lih-Jiun K, Luo JC, Lu RH, Lee SD. Delayed gastrointestinal transit in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2002;17:1254-1259. [PMID: 12423268 DOI: 10.1046/j.1440-1746.2002.02877.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
225 Liaw Y. Role of antiviral therapy of HBV in the prevention of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:S128-30. [DOI: 10.1111/j.1440-1746.2004.03662.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
226 Aono J, Yotsuyanagi H, Miyoshi H, Tsutsumi T, Fujie H, Shintani Y, Moriya K, Okuse C, Suzuki M, Yasuda K, Iino S, Koike K. Amino acid substitutions in the S region of hepatitis B virus in sera from patients with acute hepatitis. Hepatology Research 2007;37:731-9. [DOI: 10.1111/j.1872-034x.2007.00120.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
227 Lai CL, Yuen MF. The natural history of chronic hepatitis B. J Viral Hepat. 2007;14 Suppl 1:6-10. [PMID: 17958636 DOI: 10.1111/j.1365-2893.2007.00909.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 17] [Article Influence: 0.4] [Reference Citation Analysis]
228 de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5. [PMID: 1426884 DOI: 10.1016/0016-5085(92)91188-a] [Cited by in Crossref: 299] [Cited by in F6Publishing: 63] [Article Influence: 10.3] [Reference Citation Analysis]
229 Park BK, Park YN, Ahn SH, Lee KS, Chon CY, Moon YM, Park C, Han KH. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol. 2007;22:383-388. [PMID: 17295771 DOI: 10.1111/j.1440-1746.2007.04857.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
230 Yotsuyanagi H, Hino K, Tomita E, Toyoda J, Yasuda K, Iino S. Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. Journal of Hepatology 2002;37:355-63. [DOI: 10.1016/s0168-8278(02)00180-0] [Cited by in Crossref: 58] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
231 Robinson WS, Klote L, Aoki N. Hepadnaviruses in cirrhotic liver and hepatocellular carcinoma. J Med Virol. 1990;31:18-32. [PMID: 2165515 DOI: 10.1002/jmv.1890310106] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 1.0] [Reference Citation Analysis]
232 Dan YY, Lim SG. Applicability of cost-effectiveness analysis to management of chronic hepatitis B. J Gastroenterol Hepatol 2007;22:1357-9. [DOI: 10.1111/j.1440-1746.2007.05098.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
233 Merican I, Guan R, Amarapuka D, Alexander M, Chutaputti A, Chien R, Hasnian S, Leung N, Lesmana L, Phiet P, Sjalfoellah Noer H, Sollano J, Sun H, Xu D. Chronic hepatitis B virus infection in Asian countries. Journal of Gastroenterology and Hepatology 2000;15:1356-61. [DOI: 10.1046/j.1440-1746.2000.0150121356.x] [Cited by in Crossref: 305] [Cited by in F6Publishing: 284] [Article Influence: 14.5] [Reference Citation Analysis]
234 Sato M, Kamada Y, Takeda Y, Kida S, Ohara Y, Fujii H, Akita M, Mizutani K, Yoshida Y, Yamada M, Hougaku H, Takehara T, Miyoshi E. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int 2015;35:925-35. [DOI: 10.1111/liv.12478] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.9] [Reference Citation Analysis]
235 Chen YC, Huang SF, Chu CM, Liaw YF. Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. J Viral Hepat. 2012;19:138-146. [PMID: 22239503 DOI: 10.1111/j.1365-2893.2011.01450.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
236 Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, Xie Q, Chen C, Wei L, Niu J, Wang Q, Ren H, Wang Y, Jia J, Bao W, Dong Y, Trylesinski A, Naoumov NV. Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. Adv Ther 2015;32:727-41. [PMID: 26329749 DOI: 10.1007/s12325-015-0232-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
237 Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004;10:910-2. [PMID: 15040044 DOI: 10.3748/wjg.v10.i6.910] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 48] [Article Influence: 3.2] [Reference Citation Analysis]
238 Ganesan M, Eikenberry A, Poluektova LY, Kharbanda KK, Osna NA. Role of alcohol in pathogenesis of hepatitis B virus infection. World J Gastroenterol 2020;26:883-903. [PMID: 32206001 DOI: 10.3748/wjg.v26.i9.883] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
239 Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43:S173-S181. [PMID: 16447285 DOI: 10.1002/hep.20956] [Cited by in Crossref: 333] [Cited by in F6Publishing: 279] [Article Influence: 22.2] [Reference Citation Analysis]
240 Lall S, Choudhary MC, Mahajan S, Kumar G, Gupta E. Performance evaluation of TRUPCR® HBV Real-time PCR assay for Hepatitis B virus DNA quantification in clinical samples: report from a tertiary care liver centre. Virusdisease 2019;30:186-92. [PMID: 31179355 DOI: 10.1007/s13337-018-0502-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
241 Tai DI, Tsay PK, Jeng WJ, Weng CC, Huang SF, Huang CH, Lin SM, Chiu CT, Chen WT, Wan YL. Differences in liver fibrosis between patients with chronic hepatitis B and C: evaluation by acoustic radiation force impulse measurements at 2 locations. J Ultrasound Med 2015;34:813-21. [PMID: 25911714 DOI: 10.7863/ultra.34.5.813] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
242 Chan HL, Lok AS. HEPATITIS B IN ADULTS. Clinics in Liver Disease 1999;3:291-307. [DOI: 10.1016/s1089-3261(05)70069-6] [Cited by in Crossref: 10] [Article Influence: 0.5] [Reference Citation Analysis]
243 Crowley S, Tognarini D, Desmond P, Lees M, Saal G. Introduction of lamivudine for the treatment of chronic hepatitis B: Expected clinical and economic outcomes based on 4-year clinical trial data. Journal of Gastroenterology and Hepatology 2002;17:153-64. [DOI: 10.1046/j.1440-1746.2002.02673.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
244 Huang S, Chen T, Tsai S, Liaw Y. Histopathology and pathobiology of hepatotropic virus-induced liver injury. J Gastroenterol Hepatol 1997;12:S195-217. [DOI: 10.1111/j.1440-1746.1997.tb00502.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
245 Theise ND, Bodenheimer HC, Guido M. Viral Hepatitis. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 372-415. [DOI: 10.1016/b978-0-7020-6697-9.00006-6] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
246 Fung SK, Lok AS. Management of patients with hepatitis B virus-induced cirrhosis. J Hepatol 2005;42 Suppl:S54-64. [PMID: 15777573 DOI: 10.1016/j.jhep.2004.11.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
247 Hsiao TJ, Wang JD, Yang PM, Yang PC, Cheng TJ. Liver fibrosis in asymptomatic polyvinyl chloride workers. J Occup Environ Med. 2004;46:962-966. [PMID: 15354062 DOI: 10.1097/01.jom.0000137722.66767.38] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
248 Bortolotti F, Guido M, Cadrobbi P, Crivellaro C, Bartolacci S, Rugge M, Gatta A. Spontaneous regression of hepatitis B virus-associated cirrhosis developed in childhood. Dig Liver Dis. 2005;37:964-967. [PMID: 16249128 DOI: 10.1016/j.dld.2005.04.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
249 Zhang X, Lin SM, Ye F, Chen TY, Liu M, Chen YR, Zheng SQ, Zhao YR, Zhang SL. An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients. J Viral Hepat. 2011;18:e184-e190. [PMID: 21692931 DOI: 10.1111/j.1365-2893.2010.01423.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
250 Shen L, Li JQ, Zeng MD, Lu LG, Fan ST, Bao H. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol. 2006;12:1292-1295. [PMID: 16534888 DOI: 10.3748/wjg.v12.i8.1292] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
251 Areias J, Calinas F, Porto A, Carvalho A, Freitas D, Macedo G, Noronha R, Cotter J, Meliço-Silvestre A, Peixe R, Pratas J, Barrote D, Teixeira R, Augusto F, Carrilho I, Campante F, Velosa J, Carvalho L, Duarte MA, Guerreiro H, Pires C, Silva A, Cotrim I, Guedes F, Tomé L, Marcelino M, Gonçalves C, Ferreira E, Matos L, Peixe P, Esteves J, Valente T, Simões C, Marinho C, Jasmins L, Vieira MJ, Marinho R, Matos P, Estevens J, Carrasquinho J, Salcedo G, Parada P, Teixeira C. One year of Lamivudine therapy for portuguese patients with chronic hepatitis B. Clin Drug Investig 2003;23:339-46. [PMID: 17535046 DOI: 10.2165/00044011-200323050-00004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
252 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 639] [Article Influence: 77.2] [Reference Citation Analysis]
253 Chen Y, Fan C, Chen Y, Liu H, Wang S, Dong P, Li L, Ding H. Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study. Oncotarget 2017;8:58601-10. [PMID: 28938582 DOI: 10.18632/oncotarget.17380] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
254 Yang J, Zeng XM, Men YL, Zhao LS. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus--a systematic review. Virol J. 2008;5:100. [PMID: 18755018 DOI: 10.1186/1743-422x-5-100] [Cited by in Crossref: 81] [Cited by in F6Publishing: 20] [Article Influence: 6.2] [Reference Citation Analysis]
255 Liaw YF, Chen JJ, Chen TJ. Acute exacerbation in patients with liver cirrhosis: A clinicopathological study. Liver. 1990;10:177-184. [PMID: 1696678 DOI: 10.1111/j.1600-0676.1990.tb00455.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 0.9] [Reference Citation Analysis]
256 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-1125/1/142] [Reference Citation Analysis]
257 Guan R, Lui HF. Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol. 2011;2011:918017. [PMID: 21994876 DOI: 10.4061/2011/918017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
258 Fang CT, Chen PJ, Chen MY, Hung CC, Chang SC, Chang AL, Chen DS. Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection. J Hepatol 2003;39:1028-35. [PMID: 14642622 DOI: 10.1016/s0168-8278(03)00416-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
259 Laskus T, Rakela J, Tong MJ, Persing DH. Nucleotide sequence analysis of the precore region in patients with spontaneous reactivation of chronic hepatitis B. Dig Dis Sci 1994;39:2000-6. [PMID: 8082510 DOI: 10.1007/BF02088138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
260 Zhang QQ, An X, Liu YH, Li SY, Zhong Q, Wang J, Hu HD, Zhang DZ, Ren H, Hu P. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J. 2011;8:72. [PMID: 21324130 DOI: 10.1186/1743-422x-8-72] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
261 Chinese Society of Hepatology, Chinese Medical Association and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005): . Chinese Medical Journal 2007;120:2159-73. [DOI: 10.1097/00029330-200712020-00002] [Cited by in Crossref: 81] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
262 Liaw YF. Treatment of chronic hepatitis B virus infection: who, when, what for and how. J Gastroenterol Hepatol 2000;15 Suppl:E31-3. [PMID: 10921379 DOI: 10.1046/j.1440-1746.2000.02099.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
263 Mathew JL, El Dib R, Mathew PJ, Boxall EH, Brok J. Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status. Cochrane Database Syst Rev 2008;:CD006481. [PMID: 18677780 DOI: 10.1002/14651858.CD006481.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
264 Chen WT, Lee MS, Chang CL, Chiu CT, Chang ML. Retinol-binding protein-4 expression marks the short-term mortality of critically ill patients with underlying liver disease: Lipid, but not glucose, matters. Sci Rep 2017;7:2881. [PMID: 28588245 DOI: 10.1038/s41598-017-03096-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
265 Castro-e-silva Jr OD, Sankarankutty AK, Oliveira GRD, Pacheco E, Ramalho FS, Sasso KD, Tolentino E, Mente ED, França AVC, Martinelli ALC. Transplante de fígado: indicação e sobrevida. Acta Cir Bras 2002;17:83-91. [DOI: 10.1590/s0102-86502002000900018] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
266 Hollinger FB, Lau DT. Hepatitis B: The Pathway to Recovery Through Treatment. Gastroenterology Clinics of North America 2006;35:895-931. [DOI: 10.1016/j.gtc.2006.10.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
267 Huang SF, Chen YT, Lee WC, Chang IC, Chiu YT, Chang Y, Tu HC, Yuh CH, Matsuura I, Shih LY. Identification of transforming hepatitis B virus S gene nonsense mutations derived from freely replicative viruses in hepatocellular carcinoma. PLoS One. 2014;9:e89753. [PMID: 24587012 DOI: 10.1371/journal.pone.0089753] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
268 Hui AY, Chan HL, Leung NW, Hung LC, Chan FK, Sung JJ. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol. 2002;34:569-572. [PMID: 11960072 DOI: 10.1097/00004836-200205000-00018] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 3.8] [Reference Citation Analysis]
269 Shimizu I, Kohno N, Tamaki K, Shono M, Huang HW, He JH, Yao DF. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol. 2007;13:4295-4305. [PMID: 17708600 DOI: 10.3748/wjg.v13.i32.4295] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 80] [Article Influence: 6.8] [Reference Citation Analysis]
270 Leung N. Lamivudine therapy for children with chronic hepatitis B infection. Journal of Hepatology 2003;38:698-9. [DOI: 10.1016/s0168-8278(03)00046-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
271 van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 2004;39:804-810. [PMID: 14999700 DOI: 10.1002/hep.20128] [Cited by in Crossref: 242] [Cited by in F6Publishing: 216] [Article Influence: 14.2] [Reference Citation Analysis]
272 Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman HD, Peleman RR, Silva M, Roach KC, Simmons F, Milstein S, Gordon SC, Ehrinpreis MN. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat 1999;6:397-403. [PMID: 10607256 DOI: 10.1046/j.1365-2893.1999.00181.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
273 Cho HJ, Kim SS, Ahn SJ, Bae CB, Kim HG, Kim YJ, Lee SK, Song GW, Kim DJ, Hwang SG, Yang JM, Kim YB, Park YN, Cho SW, Cheong JY. Serum markers for predicting significant necroinflammatory activity in patients with chronic hepatitis B. Clin Biochem 2012;45:1564-7. [PMID: 22885475 DOI: 10.1016/j.clinbiochem.2012.07.107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
274 Sugauchi F, Ohno T, Orito E, Sakugawa H, Ichida T, Komatsu M, Kuramitsu T, Ueda R, Miyakawa Y, Mizokami M. Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol. 2003;70:537-544. [PMID: 12794715 DOI: 10.1002/jmv.10428] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 4.7] [Reference Citation Analysis]
275 Pang KR, Wu JJ, Huang DB, Tyring SK, Baron S. Biological and clinical basis for molecular studies of interferons. Methods Mol Med 2005;116:1-23. [PMID: 16007741 DOI: 10.1385/1-59259-939-7:001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
276 Kao J, Chen P, Lai M, Chen D. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004;72:363-9. [DOI: 10.1002/jmv.10534] [Cited by in Crossref: 123] [Cited by in F6Publishing: 122] [Article Influence: 7.2] [Reference Citation Analysis]
277 Han Z, He X, Peng S. Neutrophil count to albumin ratio as a prognostic indicator for HBV-associated decompensated cirrhosis. J Clin Lab Anal 2021;35:e23730. [PMID: 33609049 DOI: 10.1002/jcla.23730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol. 2009;104:1693-1699. [PMID: 19455130 DOI: 10.1038/ajg.2009.187] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 5.1] [Reference Citation Analysis]
279 Hadziyannis SJ, Papatheodoridis GV. Emerging treatments in chronic hepatitis B. Expert Opinion on Emerging Drugs 2005;9:207-21. [DOI: 10.1517/14728214.9.2.207] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
280 Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis. 2008;8:167-178. [PMID: 18053766 DOI: 10.1016/s1473-3099(07)70264-5] [Cited by in Crossref: 138] [Cited by in F6Publishing: 53] [Article Influence: 9.9] [Reference Citation Analysis]
281 Nightingale S, Stormon MO, Day AS, Webber MT, Ward KA, O’loughlin EV. Chronic hepatitis B and C infection in children in New South Wales. Medical Journal of Australia 2009;190:670-3. [DOI: 10.5694/j.1326-5377.2009.tb02633.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
282 Jafri SR, Lok AS. Antiviral Therapy for Chronic Hepatitis B. Clinics in Liver Disease 2010;14:425-38. [DOI: 10.1016/j.cld.2010.05.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
283 Schmilovitz-Weiss H, Tovar A, Halpern M, Sulkes J, Braun M, Rotman Y, Tur-Kaspa R, Ben-Ari Z. Predictive value of serum globulin levels for the extent of hepatic fibrosis in patients with chronic hepatitis B infection. J Viral Hepat. 2006;13:671-677. [PMID: 16970598 DOI: 10.1111/j.1365-2893.2006.00744.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
284 Huo TI, Wu JC, Lee PC, Tsay SH, Chang FY, Lee SD. Diabetes mellitus as a risk factor of liver cirrhosis in patients with chronic hepatitis B virus infection. J Clin Gastroenterol. 2000;30:250-254. [PMID: 10777182 DOI: 10.1097/00004836-200004000-00009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
285 Hwang SJ, Lu RH, Wood ML, Wang YJ, Chang FY, Lee SD. Comparison of the nucleic acid-based crosslinking hybridization assay and the branched DNA signal amplification assay in the quantitative measurement of serum hepatitis B virus DNA. J Clin Lab Anal 1999;13:296-300. [PMID: 10633298 DOI: 10.1002/(sici)1098-2825(1999)13:6<296::aid-jcla8>3.0.co;2-c] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
286 Liaw Y, Chu C. Hepatitis B virus infection. The Lancet 2009;373:582-92. [DOI: 10.1016/s0140-6736(09)60207-5] [Cited by in Crossref: 833] [Cited by in F6Publishing: 345] [Article Influence: 69.4] [Reference Citation Analysis]
287 Veenstra DL, Sullivan SD, Lai MY, Lee CM, Tsai CM, Patel KK. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value Health 2008;11:131-8. [PMID: 18380625 DOI: 10.1111/j.1524-4733.2007.00221.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
288 Liu ZW, Han QY, Zhang N, Kang W. Sequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis B. World J Gastroenterol 2004;10:972-6. [PMID: 15052677 DOI: 10.3748/wjg.v10.i7.972] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
289 Wang Y, Liang X, Yang J, Wang H, Tan D, Chen S, Cheng J, Chen Y, Sun J, Rong F, Yang W, Liu H, Liu Z, Zheng Y, Liang J, Li S, Liu Z, Hou J. Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B. J Viral Hepat 2018;25:598-607. [PMID: 29193542 DOI: 10.1111/jvh.12835] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
290 Tejima K, Masuzaki R, Ikeda H, Yoshida H, Tateishi R, Sugioka Y, Kume Y, Okano T, Iwai T, Gotoh H. Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly. J Gastroenterol. 2010;45:876-884. [PMID: 20339877 DOI: 10.1007/s00535-010-0233-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
291 Sheen I, Liaw Y, Lin D, Chu C. Acute exacerbations in chronic hepatitis C: a clinicopathological and prognostic study. Journal of Hepatology 1996;24:525-31. [DOI: 10.1016/s0168-8278(96)80136-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
292 Lee HW, Yoo EJ, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol. 2014;109:1241-1249. [PMID: 24957159 DOI: 10.1038/ajg.2014.157] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 11.4] [Reference Citation Analysis]
293 Perrillo R. Hepatitis B Virus Replication x Time Equals Trouble. Gastroenterology 2006;130:989-91. [DOI: 10.1053/j.gastro.2006.01.070] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
294 Johansson HE, Haenni A, Zethelius B. Platelet counts and liver enzymes after bariatric surgery. J Obes 2013;2013:567984. [PMID: 23509615 DOI: 10.1155/2013/567984] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
295 Lin X, Robinson NJ, Thursz M, Rosenberg DM, Weild A, Pimenta JM, Hall AJ. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: Review of disease progression: Chronic hepatitis B disease progression in Asia-Pacific region and Africa. Journal of Gastroenterology and Hepatology 2005;20:833-43. [DOI: 10.1111/j.1440-1746.2005.03813.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
296 van Nunen AB, Hansen BE, Suh DJ, Löhr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen HL, de Man RA. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut. 2003;52:420-424. [PMID: 12584227 DOI: 10.1136/gut.52.3.420] [Cited by in Crossref: 116] [Cited by in F6Publishing: 113] [Article Influence: 6.4] [Reference Citation Analysis]
297 Owens DK, Nease RF. Occupational exposure to human immunodeficiency virus and hepatitis B virus: A comparative analysis of risk. The American Journal of Medicine 1992;92:503-12. [DOI: 10.1016/0002-9343(92)90747-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
298 Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014;20:6262-78. [PMID: 24876747 DOI: 10.3748/wjg.v20.i20.6262] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 76] [Article Influence: 13.8] [Reference Citation Analysis]
299 Lai CJ, Terrault NA. Antiviral therapy in patients with chronic hepatitis B and cirrhosis. Gastroenterol Clin North Am 2004;33:629-54, x-xi. [PMID: 15324948 DOI: 10.1016/j.gtc.2004.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
300 Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med. 2006;119:71.e9-71.16. [PMID: 16431195 DOI: 10.1016/j.amjmed.2005.02.033] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 6.6] [Reference Citation Analysis]
301 Zhu B, Wei XX, Wang TB, Zhou YC, Liu AM, Zhang GW. Increased miR-16 expression induced by hepatitis C virus infection promotes liver fibrosis through downregulation of hepatocyte growth factor and Smad7. Arch Virol. 2015;160:2043-2050. [PMID: 26071245 DOI: 10.1007/s00705-015-2474-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
302 Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol. 2002;97:1618-1628. [PMID: 12135009 DOI: 10.1111/j.1572-0241.2002.05819.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 73] [Article Influence: 4.8] [Reference Citation Analysis]
303 Kim JW, Park SH, Louie SG. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Ann Pharmacother. 2006;40:472-478. [PMID: 16507625 DOI: 10.1345/aph.1G027] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
304 Ma H, Wei L, Guo F, Zhu S, Sun Y, Wang H. Clinical features and survival in Chinese patients with hepatitis B e antigen-negative hepatitis B virus-related cirrhosis. Journal of Gastroenterology and Hepatology 2008;23:1250-8. [DOI: 10.1111/j.1440-1746.2008.05499.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
305 Liaw Y, Sollano JD. Factors influencing liver disease progression in chronic hepatitis B. Liver International 2006;26:23-9. [DOI: 10.1111/j.1478-3231.2006.01372.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
306 Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 342-374.e17. [DOI: 10.1016/b978-0-323-35761-6.00025-0] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
307 Liaw Y, Chen T, Chu C, Lin H. Acute hepatitis delta virus superinfection in patients with liver cirrhosis. Journal of Hepatology 1990;10:41-5. [DOI: 10.1016/0168-8278(90)90071-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
308 Krahn M, Detsky AS. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis. Med Decis Making 1993;13:4-20. [PMID: 8433635 DOI: 10.1177/0272989X9301300103] [Cited by in Crossref: 44] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
309 Wiebe T, Fergusson P, Horne D, Shanahan M, Macdonald A, Heise L, Roos LL. Hepatitis B Immunization in a Low-incidence Province of Canada: Comparing Alternative Strategies. Med Decis Making 1997;17:472-82. [DOI: 10.1177/0272989x9701700413] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
310 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 84] [Cited by in F6Publishing: 75] [Article Influence: 14.0] [Reference Citation Analysis]
311 Blake M, Niklinski J, Zajac-kaye M. Interactions of the transcription factors MIBP1 and RFX1 with the EP element of the hepatitis B virus enhancer. J Virol 1996;70:6060-6. [DOI: 10.1128/jvi.70.9.6060-6066.1996] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
312 Hsu CW, Yeh CT, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology. 2007;132:543-550. [PMID: 17258721 DOI: 10.1053/j.gastro.2006.12.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
313 Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology. 2007;133:1458-1465. [PMID: 17935720 DOI: 10.1053/j.gastro.2007.08.039] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 8.5] [Reference Citation Analysis]
314 Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat. 2002;9:393-399. [PMID: 12431200 DOI: 10.1046/j.1365-2893.2002.00388.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
315 Weisberg IS, Brown RS, Sigal SH. Hepatitis B and End-Stage Liver Disease. Clinics in Liver Disease 2007;11:893-916. [DOI: 10.1016/j.cld.2007.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
316 Yang R, Gui X, Xiong Y, Gao S. Long-term follow-up of patients triply infected with HIV and hepatitis B and C viruses in a comprehensive hospital in central China. J Viral Hepat 2017;24:1192-3. [PMID: 28632964 DOI: 10.1111/jvh.12739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
317 Haché C, Villeneuve JP. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin Pharmacother. 2006;7:1835-1843. [PMID: 16925509 DOI: 10.1517/14656566.7.13.1835] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
318 Lee H, Park W, Yang JH, You KS. Management of hepatitis B virus infection. Gastroenterol Nurs 2010;33:120-6; quiz 127-8. [PMID: 20389225 DOI: 10.1097/SGA.0b013e3181d72c59] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
319 Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009;51:403-10. [PMID: 19467727 DOI: 10.1016/j.jhep.2009.04.003] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 6.9] [Reference Citation Analysis]
320 Kiyasu PK, Caldwell SH. Diagnosis and Treatment of the Major Hepatotropic Viruses. The American Journal of the Medical Sciences 1993;306:248-61. [DOI: 10.1097/00000441-199310000-00008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
321 Malkan G, Cattral MS, Humar A, Al Asghar H, Greig PD, Hemming AW, Levy GA, Lilly LB. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation. 2000;69:1403-1407. [PMID: 10798762 DOI: 10.1097/00007890-200004150-00033] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
322 Lai M, Liaw Y. Chronic Hepatitis B: Past, Present, and Future. Clinics in Liver Disease 2010;14:531-46. [DOI: 10.1016/j.cld.2010.05.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
323 Teng CF, Wu HC, Su IJ, Jeng LB. Hepatitis B Virus Pre-S Mutants as Biomarkers and Targets for the Development and Recurrence of Hepatocellular Carcinoma. Viruses 2020;12:E945. [PMID: 32859114 DOI: 10.3390/v12090945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
324 Yamaura T, Tanaka E, Matsumoto A, Rokuhara A, Orii K, Yoshizawa K, Miyakawa Y, Kiyosawa K. A case-control study for early prediction of hepatitis B e antigen seroconversion by hepatitis B virus DNA levels and mutations in the precore region and core promoter. J Med Virol. 2003;70:545-552. [PMID: 12794716 DOI: 10.1002/jmv.10429] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
325 Wong VW, Chan HL, Wong ML, Tam JS, Leung NW. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther. 2004;19:323-329. [PMID: 14984379 DOI: 10.1111/j.1365-2036.2004.01845.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
326 Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372-374. [PMID: 1808228 DOI: 10.1016/0168-8278(91)90084-o] [Cited by in Crossref: 1045] [Cited by in F6Publishing: 265] [Article Influence: 36.0] [Reference Citation Analysis]
327 Cheng H, Chang Y, Chen Y, Lee T, Tai D, Lin D. AFP-L3 in Chronic Liver Diseases with Persistent Elevation of Alpha-fetoprotein. Journal of the Chinese Medical Association 2007;70:310-7. [DOI: 10.1016/s1726-4901(08)70011-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
328 Alberti A, Fattovich G. Natural history of chronic hepatitis B. Curr hepatitis rep 2004;3:54-60. [DOI: 10.1007/s11901-004-0010-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
329 Louis-Jacques O, Olson AD. Cost-benefit analysis of interferon therapy in children with chronic active hepatitis B. J Pediatr Gastroenterol Nutr. 1997;24:25-32. [PMID: 9093982 DOI: 10.1097/00005176-199701000-00008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
330 Di Martino V, Thevenot T, Colin JF, Boyer N, Martinot M, Degos F, Coulaud JP, Vilde JL, Vachon F, Degott C. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology. 2002;123:1812-1822. [PMID: 12454838 DOI: 10.1053/gast.2002.37061] [Cited by in Crossref: 123] [Cited by in F6Publishing: 105] [Article Influence: 6.5] [Reference Citation Analysis]
331 Pang N, Zhao C, Li J, Li L, Yang X, Yang M, Wu Z, Feng D. Body mass index changes after transjugular intrahepatic portosystemic shunt in individuals with cirrhosis. Nutrition 2021;84:111095. [PMID: 33571910 DOI: 10.1016/j.nut.2020.111095] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
332 Liaw YF. Current therapeutic trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol. 1997;12:S346-S353. [PMID: 9407357 DOI: 10.1111/j.1440-1746.1997.tb00520.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 2.1] [Reference Citation Analysis]
333 Safadi R, Israeli E, Papo O, Shibolet O, Melhem A, Bloch A, Rowe M, Alper R, Klein A, Hemed N. Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol. 2003;98:2505-2515. [PMID: 14638356 DOI: 10.1111/j.1572-0241.2003.07700.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
334 Li QY, Guo ZZ, Liang J, Zhang W, Xu LM, Gao YQ, Wang XS, Xue DY, Su SB. Interleukin-10 genotype correlated to deficiency syndrome in hepatitis B cirrhosis. Evid Based Complement Alternat Med 2012;2012:298925. [PMID: 22690243 DOI: 10.1155/2012/298925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
335 Ter Borg F, Ten Kate FJ, Cuypers HT, Leentvaar-Kuijpers A, Oosting J, Wertheim-van Dillen PM, Honkoop P, Rasch MC, deMan RA, van Hattum J. Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen. Lancet. 1998;351:1914-1918. [PMID: 9654258 DOI: 10.1016/S0140-6736(97)09391-4] [Cited by in Crossref: 44] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
336 Wursthorn K, Manns MP, Wedemeyer H. Natural history: the importance of viral load, liver damage and HCC. Best Pract Res Clin Gastroenterol 2008;22:1063-79. [PMID: 19187867 DOI: 10.1016/j.bpg.2008.11.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
337 Kuo YH, Chen CH, Wang JH, Hung CH, Tseng PL, Lu SN, Changchien CS, Lee CM. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol. 2010;45:75-81. [PMID: 20030580 DOI: 10.3109/00365520903394550] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
338 Guardiola Arévalo A, Gómez Rodríguez R, Romero Gutiérrez M, Gómez Moreno AZ, García Vela A, Sánchez Simón R, Gómez Hernando C, Andrés Esteban EM. Characteristics and course of chronic hepatitis B e antigen-negative infection. Gastroenterol Hepatol 2017;40:59-69. [PMID: 28007350 DOI: 10.1016/j.gastrohep.2016.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
339 Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int. 2007;1:267-273. [PMID: 19669348 DOI: 10.1007/s12072-007-5001-0] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 6.8] [Reference Citation Analysis]
340 Xu B, Hu DC, Rosenberg DM, Jiang QW, Lin XM, Lu JL, Robinson NJ. Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. J Gastroenterol Hepatol 2003;18:1345-52. [PMID: 14675261 DOI: 10.1046/j.1440-1746.2003.03187.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
341 Lau GK. Does treatment with interferon-based therapy improve the natural history of chronic hepatitis B infection? Journal of Hepatology 2007;46:6-8. [DOI: 10.1016/j.jhep.2006.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
342 Wong WW, Woo G, Heathcote EJ, Krahn M. Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol 2013;27:137-47. [PMID: 23516678 DOI: 10.1155/2013/924640] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
343 Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver. 1989;9:235-241. [PMID: 2770436 DOI: 10.1111/j.1600-0676.1989.tb00405.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 101] [Article Influence: 3.4] [Reference Citation Analysis]
344 Chen RY, Desmond PV, Locarnini SA. Emerging therapies of hepatitis B and C. J Gastroenterol Hepatol 2002;17 Suppl:S471-81. [PMID: 12534781 DOI: 10.1046/j.1440-1746.17.s4.13.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
345 Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, Wong BC, Lai KC, Lai CL. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610-1614. [PMID: 15871997 DOI: 10.1136/gut.2005.065136] [Cited by in Crossref: 255] [Cited by in F6Publishing: 235] [Article Influence: 15.9] [Reference Citation Analysis]
346 Zimmerman HJ, Lewis JH, Kassianides C. Cirrhosis. In: Okuda K, Benhamou J, editors. Portal Hypertension. Tokyo: Springer Japan; 1991. pp. 251-70. [DOI: 10.1007/978-4-431-68361-2_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
347 Mahoney FJ. Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection. Clin Microbiol Rev 1999;12:351-66. [DOI: 10.1128/cmr.12.2.351] [Cited by in Crossref: 228] [Cited by in F6Publishing: 63] [Article Influence: 10.4] [Reference Citation Analysis]
348 Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998;28:930-938. [PMID: 9672166 DOI: 10.1016/s0168-8278(98)80339-5] [Cited by in Crossref: 304] [Cited by in F6Publishing: 82] [Article Influence: 13.2] [Reference Citation Analysis]
349 Takeda A, Jones J, Shepherd J, Davidson P, Price A. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. J Viral Hepat 2007;14:75-88. [PMID: 17244247 DOI: 10.1111/j.1365-2893.2006.00808.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
350 Ghosh S, Mondal RK, Banerjee P, Nandi M, Sarkar S, Das K, Santra A, Banerjee S, Chowdhury A, Datta S. Tracking the naturally occurring mutations across the full-length genome of hepatitis B virus of genotype D in different phases of chronic e-antigen-negative infection. Clin Microbiol Infect. 2012;18:E412-E418. [PMID: 22827722 DOI: 10.1111/j.1469-0691.2012.03975.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
351 Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination. J Gastroenterol Hepatol. 2013;28:1842-1848. [PMID: 23829381 DOI: 10.1111/jgh.12327] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
352 Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol 2006;12:6620-6. [PMID: 17075974 DOI: 10.3748/wjg.v12.i41.6620] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
353 Cheng CY, Ho CH, Wang CC, Liang FW, Wang JJ, Chio CC, Chang CH, Kuo JR. One-Year Mortality after Traumatic Brain Injury in Liver Cirrhosis Patients--A Ten-Year Population-Based Study. Medicine (Baltimore). 2015;94:e1468. [PMID: 26448001 DOI: 10.1097/md.0000000000001468] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
354 Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol. 2014;61:1407-1417. [PMID: 25178562 DOI: 10.1016/j.jhep.2014.08.033] [Cited by in Crossref: 147] [Cited by in F6Publishing: 126] [Article Influence: 21.0] [Reference Citation Analysis]
355 Hsiang JC, Bai WW, Raos Z, Stableforth W, Upton A, Selvaratnam S, Gane EJ, Gerred SJ. Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand: Cirrhosis outcomes in New Zealand. Intern Med J 2015;45:160-9. [DOI: 10.1111/imj.12624] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
356 Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49:S13-S21. [PMID: 19399811 DOI: 10.1002/hep.22881] [Cited by in Crossref: 426] [Cited by in F6Publishing: 339] [Article Influence: 35.5] [Reference Citation Analysis]
357 Yao F, Gish RG. Treatment of chronic hepatitis B: New antiviral therapies. Curr Gastroenterol Rep 1999;1:20-6. [DOI: 10.1007/s11894-999-0082-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
358 Housset C, Pol S, Carnot F, Dubois F, Nalpas B, Housset B, Berthelot P, Brechot C. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 1992;15:578-83. [DOI: 10.1002/hep.1840150404] [Cited by in Crossref: 83] [Cited by in F6Publishing: 58] [Article Influence: 2.9] [Reference Citation Analysis]
359 Tsai DS, Huang MH, Chang YS, Li TC, Peng WH. The use of Chinese herbal medicines associated with reduced mortality in chronic hepatitis B patients receiving lamivudine treatment. J Ethnopharmacol 2015;174:161-7. [PMID: 26277491 DOI: 10.1016/j.jep.2015.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
360 Nam SW, Jung JJ, Bae SH, Choi JY, Yoon SK, Cho SH, Han JY, Han NI, Yang JM, Lee YS. Clinical outcomes of delayed clearance of serum HBsAG in patients with chronic HBV infection. Korean J Intern Med. 2007;22:73-76. [PMID: 17616021 DOI: 10.3904/kjim.2007.22.2.73] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
361 Fung SK, Fontana RJ. Management of Drug-Resistant Chronic Hepatitis B. Clinics in Liver Disease 2006;10:275-302. [DOI: 10.1016/j.cld.2006.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
362 Liaw YF, Chen Y, Sheen I. Spontaneous clearance of hepatitis B surface antigen in chronic hepatitis B virus infection confers a favorable response. Hepatology 1999;29:296-296. [DOI: 10.1002/hep.510290134] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
363 Lindh M, Norkrans G, Stenqvist K, Eriksson K, Taranger J. Hepatitis B Carriers in Sweden – Effects of Immigration. Scandinavian Journal of Infectious Diseases 2009;25:411-6. [DOI: 10.3109/00365549309008520] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
364 Zheng SJ, Liu S, Liu M, McCrae MA, Li JF, Han YP, Xu CH, Ren F, Chen Y, Duan ZP. Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol 2014;20:2403-11. [PMID: 24605039 DOI: 10.3748/wjg.v20.i9.2403] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
365 Sung JJ, Chan HL, Wong ML, Tse CH, Yuen SC, Tam JS, Leung NW. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepat. 2002;9:229-234. [PMID: 12010512 DOI: 10.1046/j.1365-2893.2002.00352.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
366 Chang ML, Cheng JS, Chien RN, Liaw YF. Hepatitis Flares Are Associated With Better Outcomes Than No Flare in Patients With Decompensated Cirrhosis and Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2020;18:2064-2072.e2. [PMID: 31982607 DOI: 10.1016/j.cgh.2020.01.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
367 Liaw YF. Management of patients with chronic hepatitis B. J Gastroenterol Hepatol. 2002;17:406-408. [PMID: 11982720 DOI: 10.1046/j.1440-1746.2002.02736.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
368 Suzuki Y, Yotsuyanagi H, Okuse C, Nagase Y, Takahashi H, Moriya K, Suzuki M, Koike K, Iino S, Itoh F. Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus: a case report. World J Gastroenterol 2007;13:964-9. [PMID: 17352033 DOI: 10.3748/wjg.v13.i6.964] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
369 Yao CC, Lee CM, Hung CH, Wang JH, Hu TH, Lu SN, Changchien CS, Hsu MC, Chen CH. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion. J Gastroenterol Hepatol 2015;30:918-24. [PMID: 25532588 DOI: 10.1111/jgh.12874] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
370 Zavaglia C, Severini R, Tinelli C, Franzone JS, Airoldi A, Tempini S, Bettale G, Ideo G. A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig Dis Sci 2000;45:690-6. [PMID: 10759236 DOI: 10.1023/a:1005431323945] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
371 Wai CT, Fontana RJ. Clinical significance of hepatitis B virus genotypes, variants, and mutants. Clin Liver Dis 2004;8:321-52, vi. [PMID: 15481343 DOI: 10.1016/j.cld.2004.02.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
372 Colloredo Mels G, Bellati G, Leandro G, Brunetto MR, Vicari O, Piantino P, Borzio M, Angeli G, Ideo G, Bonino F. Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations. Arch Virol Suppl 1993;8:203-11. [PMID: 8260865 DOI: 10.1007/978-3-7091-9312-9_20] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
373 Liaw Y, Tsai S, Chang J, Sheen I, Chien R, Lin D, Chu C. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 1994;106:1048-53. [DOI: 10.1016/0016-5085(94)90766-8] [Cited by in Crossref: 99] [Cited by in F6Publishing: 89] [Article Influence: 3.7] [Reference Citation Analysis]
374 Wang Z, Sun L, Wu Y, Xia Q. Extended duration versus standard duration of peginterferon alfa-2a in treatment of chronic hepatitis B: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2016;40:195-202. [PMID: 26299874 DOI: 10.1016/j.clinre.2015.06.022] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
375 Chen C, Iloeje UH, Yang H. Long-Term Outcomes in Hepatitis B: The REVEAL-HBV Study. Clinics in Liver Disease 2007;11:797-816. [DOI: 10.1016/j.cld.2007.08.005] [Cited by in Crossref: 131] [Cited by in F6Publishing: 112] [Article Influence: 9.4] [Reference Citation Analysis]
376 Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol. 2005;43:411-417. [PMID: 16006001 DOI: 10.1016/j.jhep.2005.03.018] [Cited by in Crossref: 123] [Cited by in F6Publishing: 120] [Article Influence: 7.7] [Reference Citation Analysis]
377 Yu M, Chang H, Chen P, Liu C, Liaw Y, Lin S, Lee S, Lin S, Lin C, Chen C. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. International Journal of Epidemiology 2002;31:1008-15. [DOI: 10.1093/ije/31.5.1008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
378 Tu HAT, de Vries R, Woerdenbag HJ, Li SC, Le HH, van Hulst M, Postma MJ. Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost-Effectiveness Affordability Curves in Health Care Decision Making. Value Health Reg Issues 2012;1:7-14. [PMID: 29702830 DOI: 10.1016/j.vhri.2012.03.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
379 Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clinical Gastroenterology and Hepatology 2008;6:1315-41. [DOI: 10.1016/j.cgh.2008.08.021] [Cited by in Crossref: 315] [Cited by in F6Publishing: 276] [Article Influence: 24.2] [Reference Citation Analysis]